🇺🇸 stavudine, efavirenz, lamivudine in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 10
Most-reported reactions
- Abortion Spontaneous — 1 report (10%)
- Angina Pectoris — 1 report (10%)
- Cardiomyopathy — 1 report (10%)
- Gastritis — 1 report (10%)
- Immune System Disorder — 1 report (10%)
- Maternal Exposure During Pregnancy — 1 report (10%)
- Mitral Valve Incompetence — 1 report (10%)
- Pulmonary Tuberculosis — 1 report (10%)
- Treatment Failure — 1 report (10%)
- Tuberculosis — 1 report (10%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is stavudine, efavirenz, lamivudine approved in United States?
stavudine, efavirenz, lamivudine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for stavudine, efavirenz, lamivudine in United States?
Bristol-Myers Squibb is the originator. The local marketing authorisation holder may differ — check the official source linked above.